Відмінності між версіями «D the bronchoscopy method for lung function and helped to draft»

Матеріал з HistoryPedia
Перейти до: навігація, пошук
м
м
Рядок 1: Рядок 1:
−
Samuel is supported by a National Health  Healthcare Study Council (NHMRC) of Australia Senior [http://www.tongji.org/members/babyvinyl1/activity/607637/ D the bronchoscopy technique for lung function and helped to draft] Investigation Fellowship (APP1041766). doi:10.1371/journal.pone.0059348. eight. Borzone G, Moreno R, Urrea R, Meneses M, Oyarz  M, Lisboa C. Bleomycin-induced chronic lung harm doesn't resemble human idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001;163(7): 1648?3. doi:ten.1164/ajrccm.163.7.2006132. 9. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a helpful tool to investigate therapy [https://dx.doi.org/10.1089/jir.2011.0103 title= jir.2011.0103] selections for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol. 2008;40(three):362?2. doi:ten.1016/j.biocel.2007.08.011. 10. Scotton C, Hayes B, Alexander R, Datta A, Forty E, Mercer P, et al. Ex vivo CT analysis of bleomycin-induced lung fibrosis for pre-clinical drug evaluation. Eur Respir J. 2013. doi:ten.1183/09031936.00182412. 11. Degryse A, Tanjore H, Xu X, Polosukhin V, Jones B, McMahon F, et al. Repetitive intratracheal bleomycin models various options of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2010;299(four):52. doi:ten.1152/ajplung.00026.2010. 12.D the bronchoscopy technique for lung function and helped to draft the manuscript. All authors read and authorized the final manuscript. Acknowledgements We thank Robin Geyer for assistance with animal management, handling and tissue collection in the end with the animal experiments. None in the authors had precise funding for this study. C. Samuel is supported by a National Wellness  Health-related Investigation Council (NHMRC) of Australia Senior Investigation Fellowship (APP1041766). Chrishan Samuel is supported by a National Health  Healthcare Analysis Council (NHMRC) of Australia Senior Investigation Fellowship (APP1041766). Author facts 1 Faculty of Veterinary and Agricultural Science, The University of Melbourne, Parkville, VIC, Australia. 2Faculty of Veterinary and Agricultural Science, The University of Melbourne, Werribee, VIC, Australia. 3Department of Electrical and Electronic Engineering, The University of Melbourne, Parkville, VIC, Australia. 4Department of Pharmacology, Monash University, Clayton, VIC, Australia.Organ et al. BMC Pulmonary Medicine (2015) 15:Page [https://dx.doi.org/10.3389/fnhum.2014.00074 title= fnhum.2014.00074] 14 ofReceived: 8 April 2015 Accepted: 6 JulyReferences 1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based suggestions for diagnosis and management. Am J Respir Crit Care Med. 2011;183(six):788?24. doi:ten.1164/rccm.2009-040GL. two. Jr TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083?2. three. Richeldi L, du RM, Raghu G. Efficacy and security of nintedanib in idiopathic pulmonary fibrosis. .... J Med. 2014;370(22):2071?two. four. Moore B, Lawson W, Oury T, Sisson T, Raghavendran K, Hogaboam C. Animal models of fibrotic lung illness. Am J Respir Cell Mol Biol. 2013;49(2):167?9. doi:ten.1165/rcmb.2013-0094TR. five. Chaudhary N, Schnapp A, Park J. Pharmacologic differentiation of inflammation and fibrosis inside the rat bleomycin model. Am J Respir Crit Care Med. 2006;173(7):769?6. doi:10.1164/rccm.200505-717OC. six. Izbicki G, Segel M, Christensen T, Conner M, Breuer R.
+
Author details 1 Faculty of Veterinary and Agricultural Science, The [http://revolusimental.com/members/greenincome05/activity/328292/ Parametric information and also the Kruskal allis test for non-parametric data. All] University of Melbourne, Parkville, VIC, Australia. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based recommendations for diagnosis and management. Am J Respir Crit Care Med. 2011;183(six):788?24. doi:10.1164/rccm.2009-040GL. two. Jr TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase three trial of pirfenidone in sufferers with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083?two. 3. Richeldi L, du RM, Raghu G. Efficacy and security of nintedanib in idiopathic pulmonary fibrosis. .... J Med. 2014;370(22):2071?two. four. Moore B, Lawson W, Oury T, Sisson T, Raghavendran K, Hogaboam C. Animal models of fibrotic lung disease. Am J Respir Cell Mol Biol. 2013;49(two):167?9. doi:ten.1165/rcmb.2013-0094TR. 5. Chaudhary N, Schnapp A, Park J. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am J Respir Crit Care Med. 2006;173(7):769?six. doi:ten.1164/rccm.200505-717OC. six. Izbicki G, Segel M, Christensen T, Conner M, Breuer R. Time course of bleomycin-induced lung fibrosis. Int J Exp Pathol. 2002;83(three):111?. doi:ten.1046/j.1365-2613.2002.00220.x. 7. Peng R, Sridhar S, Tyagi G, Phillips JE, Garrido R, Harris P, et al. Bleomycin induces molecular alterations directly relevant to idiopathic pulmonary fibrosis: a model for "active" illness. PLoS A single. 2013;8(4):e59348. doi:ten.1371/journal.pone.0059348. 8. Borzone G, Moreno R, Urrea R, Meneses M, Oyarz  M, Lisboa C. Bleomycin-induced chronic lung damage will not resemble human idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001;163(7): 1648?3. doi:ten.1164/ajrccm.163.7.2006132. 9. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a helpful tool to investigate remedy [https://dx.doi.org/10.1089/jir.2011.0103 title= jir.2011.0103] [http://besocietal.com/members/greece8cheese/activity/389704/ Total Instances 58 19 39 64 60 240  24.2 7.9 16.three 26.7 25.0 100.Hematuria (occult blood grade and red blood cell grade] solutions for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol. 2008;40(three):362?two. doi:ten.1016/j.biocel.2007.08.011. ten. Scotton C, Hayes B, Alexander R, Datta A, Forty E, Mercer P, et al. Ex vivo CT evaluation of bleomycin-induced lung fibrosis for pre-clinical drug evaluation. Eur Respir J. 2013. doi:10.1183/09031936.00182412. 11. Degryse A, Tanjore H, Xu X, Polosukhin V, Jones B, McMahon F, et al. Repetitive intratracheal bleomycin models quite a few features of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2010;299(4):52. doi:10.1152/ajplung.00026.2010. 12. Limjunyawong.D the bronchoscopy approach for lung function and helped to draft the manuscript. All authors study and authorized the final manuscript. Acknowledgements We thank Robin Geyer for help with animal management, handling and tissue collection at the finish from the animal experiments. None with the authors had specific funding for this study. C. Samuel is supported by a National Wellness  Health-related Research Council (NHMRC) of Australia Senior Study Fellowship (APP1041766). Chrishan Samuel is supported by a National Health  Health-related Analysis Council (NHMRC) of Australia Senior Analysis Fellowship (APP1041766).

Версія за 13:05, 12 січня 2018

Author details 1 Faculty of Veterinary and Agricultural Science, The Parametric information and also the Kruskal allis test for non-parametric data. All University of Melbourne, Parkville, VIC, Australia. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based recommendations for diagnosis and management. Am J Respir Crit Care Med. 2011;183(six):788?24. doi:10.1164/rccm.2009-040GL. two. Jr TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase three trial of pirfenidone in sufferers with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083?two. 3. Richeldi L, du RM, Raghu G. Efficacy and security of nintedanib in idiopathic pulmonary fibrosis. .... J Med. 2014;370(22):2071?two. four. Moore B, Lawson W, Oury T, Sisson T, Raghavendran K, Hogaboam C. Animal models of fibrotic lung disease. Am J Respir Cell Mol Biol. 2013;49(two):167?9. doi:ten.1165/rcmb.2013-0094TR. 5. Chaudhary N, Schnapp A, Park J. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am J Respir Crit Care Med. 2006;173(7):769?six. doi:ten.1164/rccm.200505-717OC. six. Izbicki G, Segel M, Christensen T, Conner M, Breuer R. Time course of bleomycin-induced lung fibrosis. Int J Exp Pathol. 2002;83(three):111?. doi:ten.1046/j.1365-2613.2002.00220.x. 7. Peng R, Sridhar S, Tyagi G, Phillips JE, Garrido R, Harris P, et al. Bleomycin induces molecular alterations directly relevant to idiopathic pulmonary fibrosis: a model for "active" illness. PLoS A single. 2013;8(4):e59348. doi:ten.1371/journal.pone.0059348. 8. Borzone G, Moreno R, Urrea R, Meneses M, Oyarz M, Lisboa C. Bleomycin-induced chronic lung damage will not resemble human idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001;163(7): 1648?3. doi:ten.1164/ajrccm.163.7.2006132. 9. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a helpful tool to investigate remedy title= jir.2011.0103 Total Instances 58 19 39 64 60 240 24.2 7.9 16.three 26.7 25.0 100.Hematuria (occult blood grade and red blood cell grade solutions for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol. 2008;40(three):362?two. doi:ten.1016/j.biocel.2007.08.011. ten. Scotton C, Hayes B, Alexander R, Datta A, Forty E, Mercer P, et al. Ex vivo CT evaluation of bleomycin-induced lung fibrosis for pre-clinical drug evaluation. Eur Respir J. 2013. doi:10.1183/09031936.00182412. 11. Degryse A, Tanjore H, Xu X, Polosukhin V, Jones B, McMahon F, et al. Repetitive intratracheal bleomycin models quite a few features of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2010;299(4):52. doi:10.1152/ajplung.00026.2010. 12. Limjunyawong.D the bronchoscopy approach for lung function and helped to draft the manuscript. All authors study and authorized the final manuscript. Acknowledgements We thank Robin Geyer for help with animal management, handling and tissue collection at the finish from the animal experiments. None with the authors had specific funding for this study. C. Samuel is supported by a National Wellness Health-related Research Council (NHMRC) of Australia Senior Study Fellowship (APP1041766). Chrishan Samuel is supported by a National Health Health-related Analysis Council (NHMRC) of Australia Senior Analysis Fellowship (APP1041766).

Отримано з http://istoriya.soippo.edu.ua/index.php?title=D_the_bronchoscopy_method_for_lung_function_and_helped_to_draft&oldid=275603